The invention relates to
clostridium perfringens in excrement as a
molecular marker for grading and judging
fatty liver diseases related to metabolic dysfunction and application of the
clostridium perfringens, the
clostridium perfringens contains
alpha toxin CPA according to the types of main toxins generated by the clostridium perfringens, the coding
gene of the
alpha toxin CPA is plc
gene, and the content of the
alpha toxin CPA is determined by quantitatively detecting the plc
gene. The
molecular level detection of the clostridium perfringens in the excrement sample is realized; besides, the clostridium perfringens further contain nirA genes related to
nitrogen metabolism, the nirA genes participate in the
metabolic process related to microbial
ammonia production, the functional state of the intestinal
ammonia-producing microorganisms is reflected by detecting the expression level of the nirA genes, stable acquisition of the molecular characteristics of the
intestinal microorganisms related to the MASLD is achieved, and the application prospect is broad. A molecular basis is provided for analyzing the correlation between the abnormal
ammonia metabolism and the occurrence and development of the MASLD.